ClinicalTrials.gg
TerminatedNCT06054477Updated Feb 17, 2025

Study of ALE.C04 in Patients With Head and Neck Cancer

A Phase 1/2 interventional study of ALE.C04 and Pembrolizumab in Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Alentis Therapeutics AG. Terminated at 22 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's listed conditions name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Alentis Therapeutics AG · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

Why this study was terminated
Reprioritization of Trial

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
710th of 994
21 · median 41
Started
2023
with 67 others
Phase 1/2
157 of 1,099
39 open now
Registered
917th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 710th largest by enrollment of the 994 interventional ones that give a count, is one of 68 that started in 2023, is one of 157 in phase 1/2, and was the 917th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and to assess anti-tumor activity of ALE.C04 in combination with pembrolizumab in patients with Head and Neck Cancer.

Read the detailed description

The study comprises a phase I and a phase II. The phase I dose escalation part for both ALE.C04 monotherapy and in combination with pembrolizumab and a recommended dose for expansion (RDE) part for ALE.C04 in combination with pembrolizumab. The phase II comprises a 1:1 randomized 2 arms assessing ALE.C04 and pembrolizumab given in combination versus pembrolizumab monotherapy

03

Conditions studied

  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma

Browse trials for

Keywords

  • Immunotherapy
  • Anti-Claudin1
  • ALE.C04
  • Phase I/II
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's enrollment of 21 is below the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Alentis Therapeutics AG is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to provide written informed consents
  2. Be 18 years of age on day of signing .
  3. Have or cytologically confirmed Recurrent or (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) that is considered incurable by local therapies.
  4. Have provided tissue for claudin-1 (CLDN1), programmed death ligand-1 () and biomarker analysis in a central Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.
  5. Have based on 1.1 as determined by the site.
  6. Have a performance status of 0 or 1 on the (ECOG) Performance Scale.
  7. Have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer

Exclusion criteria

Exclusion Criteria:

  1. Has progressive disease (PD) within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC (Phase II randomized combination part only).
  2. Has had radiation therapy (or other non-systemic therapy) within 2 weeks prior to randomization or patient has not fully recovered (i.e., ≤Grade 1 or at baseline) from adverse events due to a previously administered treatment. Palliative radiotherapy to a limited field is allowed.
  3. Severe immune-related adverse events leading to discontinuation of prior immune-oncology agent only for Phase I dose escalation monotherapy and combination and Phase II monotherapy.
  4. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  5. Dermatological conditions requiring active pharmacological treatment including psoriasis, atopic dermatitis, excessively dry skin or recurrent conjunctivitis, scleroderma, vitiligo, or any other active dermatological disorder.
  6. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the clinical study, interfere with the patient's participation for the full duration of the clinical study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
  7. Has received prior therapy with an anti-programmed death (PD)-1, or anti-PD-L2 (Phase II randomized combination part only).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Phase 1 Dose Escalation

    ALE.C04 single agent: Three planned doses of ALE.C04 and ALE.C04 in combination with pembrolizumab. Once a certain dose level of ALE.C04 is considered safe and well tolerated, the first cohort of patients receiving ALE.C04 at a lower dose level combined with pembrolizumab will be initiated

    Drug: ALE.C04 · Drug: Pembrolizumab

  • Experimental
    Phase 1 Recommended Dose for Expansion

    Two ALE.C04 dose levels (higher or lower) will be considered for the combination with pembrolizumab

    Drug: ALE.C04 · Drug: Pembrolizumab

  • Active comparator
    Phase 2 Randomized Combination part

    ALE.C04 at RP2D combined to pembrolizumab compared to pembrolizumab monotherapy

    Drug: ALE.C04 · Drug: Pembrolizumab

Interventions

07

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicity (DLT)

    Phase I dose escalation

    Time frame: 21 days

  2. Incidence and severity of adverse events (AEs), serious adverse events (SAEs)

    Descriptive statistics will be used to summarize results

    Time frame: Up to 30 days after last dose - Approximately 4.5 years

  3. Confirmed Objective Response Rate (ORR) by investigators assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Proportion of patients with confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1 for Phase II

    Time frame: Up to 4.5 year

  4. Confirmed Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment according to RECIST1.1

    Time from start of study treatment to first documentation of objective progressive disease (PD) as per RECIST1.1 or to death due to any causes whichever come first during phase II

    Time frame: Up to 4.5 year

Secondary outcomes

  1. Confirmed ORR by investigators assessment according to RECIST1.1

    Proportion of patients with confirmed CR or PR according to RECIST1.1

    Time frame: up to 4.5 year

  2. Confirmed immune Objective Response Rate (iORR) by investigators assessment according to immune RECIST

    Proportion of patients with confirmed immune CR or immune PR according to immune RECIST

    Time frame: up to 4.5 year

  3. Disease Control Rate (DCR) as per investigator assessment according to RECIST1.1

    Proportion of patients with CR, PR or Stable Disease (SD) according to RECIST1.1

    Time frame: up to 4.5 years

  4. Immune Disease Control Rate (iDCR) as per investigator assessment according to immune RECIST

    Proportion of patients with immune CR, immune PR or immune SD according to immune RECIST

    Time frame: up to 4.5 years

  5. Duration Of Response (DOR)

    The time from first documentation of objective response to the first documentation of PD per RECIST 1.1 or to death due to any cause, whichever comes first.

    Time frame: up to 4.5 years

  6. Immune Duration Of Response (iDOR)

    The time from first documentation of objective response to the first documentation of immune PD per immune RECIST or to death due to any cause, whichever comes first.

    Time frame: up to 4.5 years

  7. Progression Free Survival (PFS) evaluated by investigators

    The time from start of study treatment to first documentation of objective PD per RECIST1.1 following study therapy, or to death due to any cause, whichever comes first.

    Time frame: up to 4.5 years

  8. Immune Progression Free Survival (iPFS) evaluated by investigators

    The time from start of study treatment to first documentation of objective immune PD per immune RECIST following study therapy, or to death due to any cause, whichever comes first.

    Time frame: up to 4.5 years

  9. Overall Survival (OS)

    The time from start of study treatment to date of death due to any cause.

    Time frame: up to 4.5 years

  10. Maximum serum concentration (Cmax) pharmacokinetics (PK) of ALE.C04

    Maximum serum concentration (Cmax) will be derived by non-compartmental analysis and summarized by dose cohort

    Time frame: up to 4.5 years

  11. Minimum serum concentration (Cmin) pharmacokinetics (PK) of ALE.C04

    Minimum serum concentration will be derived by non-compartmental analysis and summarized by dose cohort

    Time frame: up to 4.5 years

  12. Area under the concentration-time curve (AUC) pharmacokinetics (PK) of ALE.C04

    Area under the concentration-time curve will be derived by non-compartmental analysis and summarized by dose cohort

    Time frame: up to 4.5 years

  13. Maximum serum concentration (Cmax) Pharmacokinetics (PK) of pembrolizumab

    Maximun Serum concentration (Cmax) by time point will be reported

    Time frame: up to 4.5 years

  14. Minimum serum concentration (Cmin) Pharmacokinetics (PK) of pembrolizumab

    Minimum serum concentration (Cmin) by time point will be reported

    Time frame: up to 4.5 years

  15. Area under the concentration-time curve (AUC) Pharmacokinetics (PK) of pembrolizumab

    Area under the concentration-time curve (AUC) by time point will be reported

    Time frame: up to 4.5 years

  16. Immunogenicity of ALE.C04

    To assess the presence of serum anti-drug antibodies (ADA) against ALE.C04

    Time frame: up to 4.5 years

  17. Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30

    The C30 has 30 items in total. Among those items, 28 items are symptoms scales with score range from 1 to 4. A high score represents a high level of symptomatology. The 2 other items are global health status with score range of 1 to 7. A high score represents high quality of life.

    Time frame: Phase II combination part only - Up to 4.5 year

  18. Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Question Head and Neck module 43 (HN43)

    The HN43 has 43 items of symptoms scale with score range of 1 to 4. A high score represents a high level of symptomatology.

    Time frame: Phase II combination part only - Up to 4.5 year

08

Study locations

22 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • University of Southern California USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Yale University Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    Lake Saint Louis, Missouri 63110, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • University Health Network, Princess Margaret Cancer Centre
    Toronto, Ontario M5G 1Z5, Canada
  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre
    Bordeaux, 33075, France
  • Oncopole Claudius Regaud, Iuct-Oncopole
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, France
  • Prince Of Wales Hospital
    Hong Kong, Hong Kong
  • Candiolo cancer Center,FPO IRCCS
    Candiolo, Piedmont 10060, Italy
  • Istituto Europeo Di Oncologia S.R.L.
    Milano, 20141, Italy
  • Fondazione Irccs Istituto Nazionale Dei Tumori Di Milano
    Milan, Italy
  • National Cancer Centre Singapore
    Singapore, 168583, Singapore
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
  • Vall d'Hebron Institute of Oncology
    Barcelona, 08035, Spain
  • MD Anderson Cancer Center
    Madrid, Spain
  • Hospital Clínico Universitario de Santiago de Compostela
    Santiago De Compostela, Spain
  • Incliva Biomedical Research Institute - Hospital Clinico Universitario Valencia
    Valencia, Spain
  • Inselspital, University Hospital Bern
    Bern, 3010, Switzerland
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Feb 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2023
First posted
Sep 26, 2023
StartActual
Oct 30, 2023
Primary completionActual
Feb 12, 2025
CompletionActual
Feb 12, 2025
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06054477
Lead sponsor
Alentis Therapeutics AG
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Oct 30, 2023
Primary completion
Feb 12, 2025
Completion
Feb 12, 2025
Last update
Feb 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion